Table 3.
Prognostic value of preoperative Cyfra21-1 and SCC-Ag level in ESCC patients
|
Biomarker |
Cyfra21-1 |
SCC-Ag |
||||||
|---|---|---|---|---|---|---|---|---|
| Level | No. | Median OS | 5-year survival | P value* | No. | Median OS | 5-year survival | P value* |
| Total |
|
|
|
<0.001 |
|
|
|
<0.001 |
| Low |
198 |
91.9 |
85% |
|
103 |
89.7 |
82% |
|
| High |
181 |
46.6 |
33% |
|
276 |
63.7 |
53% |
|
| pTNM stage |
|
|
|
|
|
|
|
|
| Stage IIA |
|
|
|
<0.001 |
|
|
|
0.069 |
| Low |
75 |
102.6 |
93% |
|
46 |
85.7 |
86% |
|
| High |
52 |
59.9 |
54% |
|
81 |
78.2 |
72% |
|
| Stage IIB |
|
|
|
<0.001 |
|
|
|
<0.001 |
| Low |
123 |
84.4 |
80% |
|
57 |
73.7 |
78% |
|
| High | 129 | 41.1 | 25% | 195 | 57.1 | 45% | ||
Abbreviation: pTNM stage, pathological tumor-node-metastasis stage.
* Log-rank test.